Resistance mechanisms against osimertinib in lung adenocarcinoma cells with EGFR-activating mutation

被引：0
|
作者：
Nishihara, Shigetoshi [1 ,2 ]
Yamaoka, Toshimitsu [1 ,3 ]
Hasebe, Yuki [1 ]
Ishikawa, Fumihiro [4 ]
Kusumoto, Sojiro [3 ]
Ohmori, Tohru [3 ]
Sagara, Hironori [3 ]
Yoshida, Hitoshi [2 ]
Tsurutani, Junjii [1 ]
机构：
[1] Showa Univ, Adv Canc Trans Res Inst, Tokyo, Japan
[2] Showa Univ, Div Gastroenterol, Dept Med, Med Sch, Tokyo, Japan
[3] Showa Univ, Div Allergol & Respi Med, Dept Med, Med Sch, Tokyo, Japan
[4] Showa Univ, Ctr Biotechnol, Tokyo, Japan
来源：
CANCER SCIENCE | 2023年 / 114卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P-2365
引用
收藏
页码：1494 / 1494
页数：1
相关论文
共 50 条
  • [1] Diverse Mechanisms of Resistance against Osimertinib, a Third-Generation EGFR-TKI, in Lung Adenocarcinoma Cells with an EGFR-Activating Mutation
    Nishihara, Shigetoshi
    Yamaoka, Toshimitsu
    Ishikawa, Fumihiro
    Ohmori, Tohru
    Ando, Koichi
    Kusumoto, Sojiro
    Kishino, Yasunari
    Manabe, Ryo
    Hasebe, Yuki
    Sagara, Hironori
    Yoshida, Hitoshi
    Tsurutani, Junji
    CELLS, 2022, 11 (14)
  • [2] Effects of secondary EGFR mutations on resistance against upfront osimertinib in cells with EGFR-activating mutations in vitro
    Nishino, Masaya
    Suda, Kenichi
    Kobayash, Yoshihisa
    Ohara, Shuta
    Fujino, Toshio
    Koga, Takamasa
    Chiba, Masato
    Shimoji, Masaki
    Tomizawa, Kenji
    Takemoto, Toshiki
    Mitsudomi, Tetsuya
    LUNG CANCER, 2018, 126 : 149 - 155
  • [3] The Incidence of EGFR-Activating Mutations in Bone Metastases of Lung Adenocarcinoma
    Krawczyk, Pawel
    Nicos, Marcin
    Ramlau, Rodryg
    Powrozek, Tomasz
    Wojas-Krawczyk, Kamila
    Sura, Sylwia
    Jarosz, Bozena
    Szumilo, Justyna
    Warda, Edward
    Mazurkiewicz, Tomasz
    Sawicki, Marek
    Milanowski, Janusz
    PATHOLOGY & ONCOLOGY RESEARCH, 2014, 20 (01) : 107 - 112
  • [4] Mechanisms of Osimertinib Resistance in EGFR Mutant Lung Cancer
    Westover, D.
    Qiao, H.
    Ichihara, E.
    Meador, C. B.
    Lovly, C. M.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (08) : S1546 - S1546
  • [5] Novel two mechanisms for acquired EGFR-TKI resistance in lung cancer cells harboring EGFR activating mutation
    Izumi, Hiroto
    Kanda, Rina
    Murakami, Yuichi
    Morimoto, Yasuo
    Ono, Mayumi
    EUROPEAN RESPIRATORY JOURNAL, 2014, 44
  • [6] Novel two mechanisms for acquired EGFR-TKI resistance in lung cancer cells harboring EGFR activating mutation
    Izumi, Hiroto
    Kanda, Rina
    Murakami, Yuichi
    Morimoto, Yasuo
    Ono, Mayumi
    EUROPEAN RESPIRATORY JOURNAL, 2014, 44
  • [7] Osimertinib in NSCLC With Atypical EGFR-Activating Mutations: A Retrospective Multicenter Study
    Ji, Jingran
    Aredo, Jacqueline, V
    Piper-Vallillo, Andrew
    Huppert, Laura
    Rotow, Julia K.
    Husain, Hatim
    Stewart, Susan
    Cobb, Rosemary
    Wakelee, Heather A.
    Blakely, Collin M.
    Wong, Melisa L.
    Gubens, Matthew A.
    Madani, Mohammad H.
    Digumarthy, Subba R.
    Mccoach, Caroline
    Piotrowska, Zofia
    Neal, Joel W.
    Riess, Jonathan W.
    JTO CLINICAL AND RESEARCH REPORTS, 2023, 4 (03):
  • [8] Subclassification of patients with lung adenocarcinoma harboring EGFR-activating mutations by gene expression profiling
    Kenmotsu, Hirotsugu
    Serizawa, Masakuni
    Isaka, Mitsuhiro
    Kojima, Hideaki
    Murakami, Haruyasu
    Nagashima, Takeshi
    Sugino, Takashi
    Ohshima, Keiichi
    Urakami, Kenichi
    Kusuhara, Masatoshi
    Yamaguchi, Ken
    Ohde, Yasuhisa
    Takahashi, Toshiaki
    CANCER SCIENCE, 2018, 109 : 1410 - 1410
  • [9] On-target Resistance to the Mutant-Selective EGFR Inhibitor Osimertinib Can Develop in an Allele-Specific Manner Dependent on the Original EGFR-Activating Mutation
    Brown, Benjamin P.
    Zhang, Yun-Kai
    Westover, David
    Yan, Yingjun
    Qiao, Huan
    Huang, Vincent
    Du, Zhenfang
    Smith, Jarrod A.
    Ross, Jeffrey S.
    Miller, Vincent A.
    Ali, Siraj
    Bazhenova, Lyudmila
    Schrock, Alexa B.
    Meiler, Jens
    Lovly, Christine M.
    CLINICAL CANCER RESEARCH, 2019, 25 (11) : 3341 - 3351
  • [10] Subclassification of patients with lung adenocarcinoma harboring EGFR-activating mutations by gene expression profiling
    Kenmotsu, Hirotsugu
    Serizawa, Masakuni
    Isaka, Mitsuhiro
    Kojima, Hideaki
    Takahashi, Shoji
    Ono, Akira
    Naito, Tateaki
    Murakami, Haruyasu
    Nagashima, Takeshi
    Ohnami, Shumpei
    Ohshima, Keiichi
    Urakami, Kenichi
    Kusuhara, Masatoshi
    Yamaguchi, Ken
    Sugino, Takashi
    Ohde, Yasuhisa
    Takahashi, Toshiaki
    CANCER RESEARCH, 2018, 78 (13)
12345